News
See whats happening in Health sector right now
-
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
The regulation finalised Monday by the Food and Drug Administration will gradually phase in oversight of new tests developed by laboratories, a multibillion-dollar industry that regulators say poses growing risks to Americans. The goal is to ensure that new tests for cancer, heart disease, COVID-19, genetic conditions and many other illnesses are safe, accurate and reliable.
-
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
-
Application in SC seeking medical expert panel to examine Covishield vaccine side effects
-
EU drug watchdog urges Covid-19 vaccine update
-
AstraZeneca reaffirms vaccine safety amidst rare side effect concerns
-
Health an orphan, Ayushman Bharat insurance scheme poorly structured: IMA chief
-
India’s rising cancer epidemic: Carcinogen-laden spices the root cause?
-
Baba Ramdev crossed red line with false claims of curing Covid, calling modern medicine 'stupid': IMA president
-
MDH, Everest row: Australia is the latest country to put spice makers on watch list
Most Read
More in News
-
Rajasthan: 44 health department employees issued show-cause notices for remaining absent
Director of Public Health Department, Dr Ravi Prakash Mathur said in a statement that during a surprise inspection in three offices of the Jaipur zone, instructions were given to issue show-cause notices to 44 staff members who remained absent without notice.
-
US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions.
-
UnitedHealth is not too big to fail, CEO tells Senate panel
Senators grilled Witty during the first of two scheduled testimonies in front of Congressional panels on the recent cyberattack on UnitedHealth's technology unit that impacted almost all patients and providers.
-
GSK raises profit outlook on strong vaccine, HIV drug sales
The London-listed drugmaker said it expected a rise of 8% to 10% in annual adjusted earnings per share, up from the 6%-9% growth previously forecast. It expects 2024 sales to grow at the upper end of its 5% to 7% forecast range.
-
Stryker lifts 2024 profit forecast on strong demand for medical devices, implants
The joint-implant maker now sees its annual profit per share to be between $11.85 and $12.05, raised from the previous range of between $11.70 and $12. The analysts' average estimate for 2024 is pegged at $11.85 per share.
-
China: Covid-19 whistleblower scientist regains lab Access after public protest
The images and stories of Zhang’s protest resonated across various platforms, eventually putting pressure on the local authorities to address the situation. By early Wednesday, Zhang announced through a post on Weibo that a "tentative agreement" had been reached with the medical center. This agreement temporarily reinstated his team's access to their lab and initiated negotiations to potentially relocate the lab without disrupting their critical research activities.
-
J&J advances $6.475 billion settlement of talc cancer lawsuits
The deal would allow it to resolve the lawsuits through a third bankruptcy filing of a subsidiary company. It will begin a three month voting period in hopes of reaching consensus on a settlement of all current and future ovarian cancer claims. Ovarian cancer claims account for 99% of the talc-related lawsuits filed against J&J, including about 54,000 lawsuits that are centralized in a New Jersey federal court proceeding.
-
FDA brings lab tests under federal oversight in bid to improve accuracy and safety
The regulation finalised Monday by the Food and Drug Administration will gradually phase in oversight of new tests developed by laboratories, a multibillion-dollar industry that regulators say poses growing risks to Americans. The goal is to ensure that new tests for cancer, heart disease, COVID-19, genetic conditions and many other illnesses are safe, accurate and reliable.
-
Study examines genetic basis for blood pressure, risk for hypertension
Data from more than a million people were analysed to discover regions on the genome, including over a 100 new ones, linked to blood pressure. The international study, led by Queen Mary University of London, UK, is published in the journal Nature Genetics.
-
Optomed Oyj, AEYE Health say portable device to detect eye issues gets FDA nod
In a procedure that takes a minute, the device takes images from each eye using a special camera and through artificial intelligence captures and analyses data on the retina to help diagnose diseases including diabetes that could cause blindness.
-
Denmark to restrict Ozempic, other GLP-1 drugs, to treat type 2 diabetes
In 2023, 50 per cent of new patients suffering from type 2 diabetes began treatment with a reimbursed GLP-1 drug without trying a cheaper alternative first, the Medicines Agency said.
-
AI cannot replace doctors, says IMA chief
"Nobody can replace a doctor. As long as the patient is vulnerable and is in a situation where he is so helpless that no science can treat him, only that touch, that hope, that eye contact, that assurance of a doctor can work," said IMA Chief.
-
Florida's 6-week abortion ban takes effect as doctors worry women will lose access to health care
The Florida Supreme Court, with five of its seven members appointed by Republican Gov. Ron DeSantis, ruled 6-1 last month to uphold the state's ban on most abortions after 15 weeks of pregnancy, which cleared the way for the six-week ban.
-
Application in SC seeking medical expert panel to examine Covishield vaccine side effects
The plea has been moved by advocate Vishal Tiwari, who also urged the court to issue directions to the Centre to establish a vaccine damage payment system for the citizens who became severely disabled as a result of a vaccination drive during COVID 19.
-
Centre needs to work on war footing to deal with rare side effects of Covishield: AAP
UK-headquartered pharmaceutical giant AstraZeneca has admitted that in "very rare cases", its COVID-19 vaccine can cause a blood clot-related side-effect but the causal link is unknown, according to court papers being quoted in the UK media.
-
GLP-1R agonists clinical trial design needs to be improved for reassuring drugs benefits : GlobalData
As per a survey conducted by GlobalData, a good implementation in obesity clinical trial design could use methods such as bioelectrical impedance analysis (BIA) and DEXA which can better assess fat loss and body composition in trial subjects
-
CARE hospital unveils digestive disease and liver transplant institute in Hyderabad
The institute is based in Hitech-City Hyderabad and will provide comprehensive care for liver, gastrointestinal, and pancreatic ailments with utmost precision, ensuring the best possible outcomes for patients.
-
Almost all US hospitals took financial hit from Change hack, AHA says
The association, which represents almost 5,000 hospitals and healthcare systems in the United States, sent the letter on Monday ahead of Wednesday's Congressional hearings on cybersecurity vulnerabilities in the healthcare sector.
-
SC pulls up Uttarakhand licensing body over delayed Patanjali action
In an affidavit filed on Monday, the licensing authority apologised for any "inadvertent and unintentional" non-compliance with the orders of the Supreme Court. It also informed the SC that a criminal complaint had been filed against Patanjali, Ramdev and Balkrishna and Divya Pharmacy before the chief judicial magistrate, Haridwar under the Drugs and Magic Remedies (Objectionable Advertisements) Act 1954.
-
Weight-loss drug drives Eli Lilly to raise 2024 sales forecast by $2 billion
The drugmaker has six manufacturing sites for the medicines. Lilly said it has broken ground at its $2.5 billion manufacturing site in Germany, and expects its Concord, North Carolina site to begin producing Zepbound and Mounjaro as early as the end of the year.